FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2907622015> ?p ?o ?g. }

• W2907622015 endingPage "2084.e2" @default.
• W2907622015 startingPage "2076" @default.
• W2907622015 abstract "Background & AimsPrimary biliary cholangitis (PBC) predominantly affects middle-aged women; there are few data on disease phenotypes and outcomes of PBC in men and younger patients. We investigated whether differences in sex and/or age at the start of ursodeoxycholic acid (UDCA) treatment are associated with response to therapy, based on biochemical markers, or differences in transplant-free survival.MethodsWe performed a longitudinal retrospective study of 4355 adults in the Global PBC Study cohort, collected from 17 centers across Europe and North America. Patients received a diagnosis of PBC from 1961 through 2014. We evaluated the effects of sex and age on response to UDCA treatment (based on GLOBE score) and transplant-free survival using logistic regression and Cox regression analyses, respectively.ResultsMale patients were older at the start of treatment (58.3±12.1 years vs 54.3±11.6 years for women; P<.0001) and had higher levels of bilirubin and lower circulating platelet counts (P<.0001). Younger patients (45 years or younger) had increased serum levels of transaminases than older patients (older than 45 years). Patients older than 45 years at time of treatment initiation had increased odds of a biochemical response to UDCA therapy, based on GLOBE score, compared to younger patients. The greatest odds of response to UDCA were observed in patients older than 65 years (odds ratio compared to younger patients 45 years or younger, 5.48; 95% CI, 3.92–7.67; P<.0001). Risk of liver transplant or death (compared to a general population matched for age, sex, and birth year) decreased significantly with advancing age: hazard ratio for patients 35 years or younger, 14.59 (95% CI, 9.66–22.02) vs hazard ratio for patients older than 65 years, 1.39 (95% CI, 1.23–1.57) (P<.0001). On multivariable analysis, sex was not independently associated with response or transplant-free survival.ConclusionIn longitudinal analysis of 4355 adults in the Global PBC Study, we associated patient age, but not sex, with response to UDCA treatment and transplant-free survival. Younger age at time of treatment initiation is associated with increased risk of treatment failure, liver transplant, and death. Primary biliary cholangitis (PBC) predominantly affects middle-aged women; there are few data on disease phenotypes and outcomes of PBC in men and younger patients. We investigated whether differences in sex and/or age at the start of ursodeoxycholic acid (UDCA) treatment are associated with response to therapy, based on biochemical markers, or differences in transplant-free survival. We performed a longitudinal retrospective study of 4355 adults in the Global PBC Study cohort, collected from 17 centers across Europe and North America. Patients received a diagnosis of PBC from 1961 through 2014. We evaluated the effects of sex and age on response to UDCA treatment (based on GLOBE score) and transplant-free survival using logistic regression and Cox regression analyses, respectively. Male patients were older at the start of treatment (58.3±12.1 years vs 54.3±11.6 years for women; P<.0001) and had higher levels of bilirubin and lower circulating platelet counts (P<.0001). Younger patients (45 years or younger) had increased serum levels of transaminases than older patients (older than 45 years). Patients older than 45 years at time of treatment initiation had increased odds of a biochemical response to UDCA therapy, based on GLOBE score, compared to younger patients. The greatest odds of response to UDCA were observed in patients older than 65 years (odds ratio compared to younger patients 45 years or younger, 5.48; 95% CI, 3.92–7.67; P<.0001). Risk of liver transplant or death (compared to a general population matched for age, sex, and birth year) decreased significantly with advancing age: hazard ratio for patients 35 years or younger, 14.59 (95% CI, 9.66–22.02) vs hazard ratio for patients older than 65 years, 1.39 (95% CI, 1.23–1.57) (P<.0001). On multivariable analysis, sex was not independently associated with response or transplant-free survival. In longitudinal analysis of 4355 adults in the Global PBC Study, we associated patient age, but not sex, with response to UDCA treatment and transplant-free survival. Younger age at time of treatment initiation is associated with increased risk of treatment failure, liver transplant, and death." @default.
• W2907622015 created "2019-01-11" @default.
• W2907622015 creator A5004457925 @default.
• W2907622015 creator A5008360462 @default.
• W2907622015 creator A5009192230 @default.
• W2907622015 creator A5009238813 @default.
• W2907622015 creator A5010905606 @default.
• W2907622015 creator A5013728497 @default.
• W2907622015 creator A5017441523 @default.
• W2907622015 creator A5021364484 @default.
• W2907622015 creator A5025186476 @default.
• W2907622015 creator A5025477372 @default.
• W2907622015 creator A5026789922 @default.
• W2907622015 creator A5028517177 @default.
• W2907622015 creator A5031051209 @default.
• W2907622015 creator A5042923287 @default.
• W2907622015 creator A5043626370 @default.
• W2907622015 creator A5050695886 @default.
• W2907622015 creator A5052219587 @default.
• W2907622015 creator A5052731848 @default.
• W2907622015 creator A5060621275 @default.
• W2907622015 creator A5065028057 @default.
• W2907622015 creator A5065511179 @default.
• W2907622015 creator A5071407810 @default.
• W2907622015 creator A5073803865 @default.
• W2907622015 creator A5080844718 @default.
• W2907622015 creator A5083542745 @default.
• W2907622015 creator A5089811094 @default.
• W2907622015 creator A5090413862 @default.
• W2907622015 creator A5090469290 @default.
• W2907622015 creator A5091028785 @default.
• W2907622015 date "2019-09-01" @default.
• W2907622015 modified "2023-10-15" @default.
• W2907622015 title "Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis" @default.
• W2907622015 cites W1071546559 @default.
• W2907622015 cites W1965196279 @default.
• W2907622015 cites W1968791123 @default.
• W2907622015 cites W1972145571 @default.
• W2907622015 cites W1972691360 @default.
• W2907622015 cites W1996647629 @default.
• W2907622015 cites W2001928607 @default.
• W2907622015 cites W2005086332 @default.
• W2907622015 cites W2005913737 @default.
• W2907622015 cites W2026102665 @default.
• W2907622015 cites W2027862649 @default.
• W2907622015 cites W2028798921 @default.
• W2907622015 cites W2032058959 @default.
• W2907622015 cites W2034459624 @default.
• W2907622015 cites W2071394537 @default.
• W2907622015 cites W2098592586 @default.
• W2907622015 cites W2141267824 @default.
• W2907622015 cites W2142917855 @default.
• W2907622015 cites W2153174384 @default.
• W2907622015 cites W2406168974 @default.
• W2907622015 cites W2605729742 @default.
• W2907622015 cites W4211101039 @default.
• W2907622015 cites W4295008070 @default.
• W2907622015 doi "https://doi.org/10.1016/j.cgh.2018.12.028" @default.
• W2907622015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30616022" @default.
• W2907622015 hasPublicationYear "2019" @default.
• W2907622015 type Work @default.
• W2907622015 sameAs 2907622015 @default.
• W2907622015 citedByCount "50" @default.
• W2907622015 countsByYear W29076220152019 @default.
• W2907622015 countsByYear W29076220152020 @default.
• W2907622015 countsByYear W29076220152021 @default.
• W2907622015 countsByYear W29076220152022 @default.
• W2907622015 countsByYear W29076220152023 @default.
• W2907622015 crossrefType "journal-article" @default.
• W2907622015 hasAuthorship W2907622015A5004457925 @default.
• W2907622015 hasAuthorship W2907622015A5008360462 @default.
• W2907622015 hasAuthorship W2907622015A5009192230 @default.
• W2907622015 hasAuthorship W2907622015A5009238813 @default.
• W2907622015 hasAuthorship W2907622015A5010905606 @default.
• W2907622015 hasAuthorship W2907622015A5013728497 @default.
• W2907622015 hasAuthorship W2907622015A5017441523 @default.
• W2907622015 hasAuthorship W2907622015A5021364484 @default.
• W2907622015 hasAuthorship W2907622015A5025186476 @default.
• W2907622015 hasAuthorship W2907622015A5025477372 @default.
• W2907622015 hasAuthorship W2907622015A5026789922 @default.
• W2907622015 hasAuthorship W2907622015A5028517177 @default.
• W2907622015 hasAuthorship W2907622015A5031051209 @default.
• W2907622015 hasAuthorship W2907622015A5042923287 @default.
• W2907622015 hasAuthorship W2907622015A5043626370 @default.
• W2907622015 hasAuthorship W2907622015A5050695886 @default.
• W2907622015 hasAuthorship W2907622015A5052219587 @default.
• W2907622015 hasAuthorship W2907622015A5052731848 @default.
• W2907622015 hasAuthorship W2907622015A5060621275 @default.
• W2907622015 hasAuthorship W2907622015A5065028057 @default.
• W2907622015 hasAuthorship W2907622015A5065511179 @default.
• W2907622015 hasAuthorship W2907622015A5071407810 @default.
• W2907622015 hasAuthorship W2907622015A5073803865 @default.
• W2907622015 hasAuthorship W2907622015A5080844718 @default.
• W2907622015 hasAuthorship W2907622015A5083542745 @default.
• W2907622015 hasAuthorship W2907622015A5089811094 @default.
• W2907622015 hasAuthorship W2907622015A5090413862 @default.
• W2907622015 hasAuthorship W2907622015A5090469290 @default.
• W2907622015 hasAuthorship W2907622015A5091028785 @default.

• next